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It was with considerable interest that I read the
case report of Vlachaki et al.,1 ‘‘Delayed response
to anti-tuberculosis treatment in a patient on
infliximab’’, in the May 2005 issue of your journal.
However, I believe the authors’ main conclusion,
that the prolonged illness was due to prolonged
anti-TNF activity of infliximab, is incorrect. In-
stead, I believe it is much more likely that it
represents immune reconstitution inflammatory
syndrome (IRIS) due to infliximab withdrawal.
IRIS, or paradoxical worsening, typically presents
as hectic fevers, lymphadenopathy, worsened
pulmonary infiltrates, effusions, hypoxia, and oc-
casionally, the evolution of new lesions not clini-
cally apparent prior to starting treatment. IRIS
occurs in its most complete form in persons starting
treatment for both AIDS and tuberculosis,2–7 but
has also been described in the context of other HIV-
associated infections, and in patients with tuber-
culosis without HIV infection.8–10 In AIDS cases with
tuberculosis, IRIS onset is closely related tempo-
rally to the initiation of antiretroviral therapy
(ART).3 Baseline risk factors for IRIS in AIDS/TB
include disseminated or extrapulmonary tubercu-
losis, low initial CD4 count, and non-reactive
tuberculin skin tests. Patients with a vigorous
response to ART (as assessed by changes in viral
load or CD4 count) are also at increased risk.3,11
Little is known regarding the immunology of IRIS,
except that nearly all cases convert to strongly
reactive tuberculin skin tests as the syndrome
evolves.3 There are no specific diagnostic tests for
IRIS. However, it is a clinical hallmark of IRIS that
the magnitude of the host immune response is
disproportionate to the burden of infection, which
in TB-associated cases, usually has declined sub-
stantially by the time IRIS is diagnosed.
Infliximab (anti-TNF monoclonal antibody) is
licensed in the US for treatment of Crohn’s disease
and rheumatoid arthritis. It is administered periodi-
cally by intravenous infusion, usually every 4–6
weeks. In addition to blocking soluble TNF, inflix-ee front matter & 2005 Elsevier Ltd. All rights reserv
med.2005.06.010imab inhibits T cell activation and interferon g
expression.12,13 Its combined effects on TNF and
IFNg may account for the high risk infliximab poses
for reactivation of latent TB infection, which has
been estimated in Europe to be as high as 173 cases
per 100,000 persons per year.14 This risk is signifi-
cantly greater than that of etanercept,15,16 a soluble
TNF receptor that does not block IFNg expression.13
A recent retrospective study by Garcia Vidal
et al.17 described typical IRIS-type paradoxical
reactions due to withdrawal of infliximab following
the diagnosis of tuberculosis in four patients with
autoimmune diseases. All four patients presented
with disseminated or extrapulmonary tuberculosis
and subsequently had infliximab treatment discon-
tinued. The interval until IRIS occurrence was from
5 to 16 weeks; however, this may have been
influenced by the case definition, which required
an interval of at least 4 weeks for inclusion in the
study. Three of the four cases required corticoster-
oids or surgical intervention.
In the present case report, Vlachaki attributes the
delayed therapeutic response to ‘‘the long term
immunosuppressive action of infliximab’’. It is not
clear how the authors made this assessment, since
the tuberculin skin test was not repeated, nor were
any in vitro tests performed to measure mycobacter-
ial T cell responses. Indeed, the return of active
spondylitis would appear to indicate a lack of
prolonged effect. The authors implied that immunity
is required for sterilization of mycobacterial infec-
tion, and that the delayed resolution of the
granulomatous host response must therefore indicate
delayed resolution of infection. However, they report
the results of four bronchoscopic diagnostic proce-
dures, performed at diagnosis, and after 20 days, 3
months, and 12 months of treatment. Specimens
from the first procedure were positive for Mycobac-
terium tuberculosis by both stain and culture; those
from the second, by culture only. Subsequent speci-
mens were negative. This cannot be described as a
delayed microbiologic response to therapy.
More importantly, the concept that host immu-
nity facilitates sterilization during TB chemother-
apy is not likely correct. The capacity of humaned.
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Table 1 Experimental evidence of antagonism between immunity and sterilization during tuberculosis
treatment.
Author Study design Main findings
Karakousis et al.18 Murine M. tuberculosis infection in
subcutaneously implanted permeable
hollow fibers
Granuloma formation decreased the
bactericidal effect of isoniazid
Dhillon and Mitchison.20 Guinea pig M. tuberculosis infection
with or without prior BCG vaccination
Prior BCG vaccination decreased the
bactericidal effect of isoniazid
Wallis et al.21 Human whole blood culture model of
intracellular M. tuberculosis infection
Immune control of intracellular M.
tuberculosis growth decreased the
intracellular bactericidal effect of
ofloxacin
Johnson et al.22 Prospective randomized clinical trial of
IL-2 vs. placebo during first month of TB
therapy in 110 HIV uninfected subjects
IL-2 delayed the clearance of viable M.
tuberculosis from sputum and delayed
sputum culture conversion
Wallis et al.23 Prospective controlled clinical trial of
etanercept vs. placebo during first
month of TB therapy in subjects with
HIV infection and CD4 4200/ml in 16
subjects and 42 controls
Anti-TNF therapy with etanercept
(soluble TNF receptor) accelerated
sputum culture conversion by 1 week
Mayanja-Kizza et al.24 Prospective controlled clinical trial of
high dose prednisolone vs. placebo
during the first month of TB therapy in
189 subjects with HIV infection and CD4
4200/ml
Anti-TNF therapy with prednisolone
2.75mg/kg/d accelerated sputum
culture conversion by 1 month
Sonnenberg et al.25 Prospective case control study of
recurrent tuberculosis
In the absence of ART, HIV infection
increased the risk of recurrence due to
reinfection but decreased the risk of
RFLP-confirmed relapse
Weiner et al.26 Prospective TB Trials Consortium clinical
trial
Two month sputum culture conversion
was superior in HIV-infected TB cases
Narita et al.3 Retrospective case control study of IRIS
in HIV+TB
TB relapse risk was increased 6 fold in
patients with IRIS
el Sadr et al.27 Prospective ACTG/CPCRA clinical trial HIV infection increased the rate of 2
month sputum culture conversion and
decreased the risk of relapse compared
to historic controls
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limited. Granulomas therefore serve to contain an
infection that cannot otherwise be eradicated by
host defenses. Mycobacteria contained within
granulomas face a hostile microenvironment with
low pH, oxygen, and other nutrients. Sequestered
mycobacteria adapt to these harsh conditions with
profound alterations in gene expression profiles,
resulting in reduced replication and reduced aero-
bic metabolism.18 This adaptation forms the basis
of clinical latency in tuberculosis. Granulomas may
thus paradoxically protect sequestered mycobac-
teria from administered chemotherapy by reducing
drug penetration, and by reducing the level of
expression of the molecular targets of these drugs.
Experimental evidence indicating antagonism be-
tween immunity and sterilization in tuberculosis is
summarized in Table 1. The report most pertinentto the case in question is that of Narita et al.,3 a
retrospective case-control study of AIDS/TB IRIS.
The authors found that IRIS increased by six fold the
subsequent risk of TB relapse.
Based on this evidence, there is reason to believe
that infliximab may hasten, rather than delay, the
clinical and microbiologic response to tuberculosis
therapy,19 and that its withdrawal at the time of TB
diagnosis may be problematic. Further studies of
the management of tuberculosis in patients on
infliximab therapy are warranted.References
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